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Introduction
Over the last decades, the knowledge of the cellular and molecu-
lar biology of ESFT has increased remarkably and has led to the 
development of multidisciplinary therapeutic strategies. However, 
the prognosis and survival of patients with metastatic or recur-
rent disease remains still very poor. Here, we focus on the current 
state-of-the-art in the research of ESFT and review carefully the 
main critical points that will highlight the most promising bio-
logical targets amenable to future therapies.
Chromosomal Translocations in ESFT: Specificity, 
Gene and Protein Fusions, Functions
The ESFT family comprises morphologically heterogeneous 
tumors that are characterized by nonrandom chromosomal trans-
locations involving the EWS gene and one of several members of 
the ETS family of transcription factor genes.1 EWS-FLI1 fusions 
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are detected in roughly 90% of ESFT; EWS-ERG are present in 
5% of cases, while 3% represent some other type of fusion of 
EWS with a member of the ETS family of transcription factor 
genes (Table 1). These fusions are specific to this neoplasia, as 
PCR studies of other tumors that could be included in a differen-
tial diagnosis, such as central primitive neuroectodermic tumors, 
neuroblastomas, rhabdomyosarcomas, adamantinomas and giant 
cell tumors, have repeatedly yielded negative results.2 The two 
main sources of variability in the translocations are, on the one 
hand, the EWS fusion “companion” (one member of the ETS 
gene family, such as FLI1, ERG, ETV1, E1A or FEV ), and on the 
other, the location of the translocation break point within each 
gene involved. In addition to the usual prognostic factors of this 
neoplasia (stage, localization, volume of the primary tumor, age 
and response to treatment), recent studies suggest the contribu-
tion of molecular heterogeneity toward the prognosis in Ewing 
sarcoma (ES).
The translocation t(11;22)(q24;q12) is the most common in 
ES, associated with 90% of cases, and this high specificity sug-
gests that the product of this rearrangement is involved in the 
formation of these malignancies. This translocation leads to an 
in-frame fusion of EWS at 22q12 to FLI1 at 11q24 and the forma-
tion of the EWS-FLI1 fusion protein. The EWS protein is pre-
dicted to be an RNA-binding protein containing a transcriptional 
activation domain(s) in the N-terminus and an RNA recognition 
motif in its C-terminus.3,4 It belongs to a subgroup of RNA-
binding proteins called the TET family, which also includes the 
liposarcoma/fusion protein (TLS/FUS), and the human TATA 
binding protein-associated factor (hTAFII68).5,6 Three key 
features indicate that the EWS protein is encoded by a house-
keeping gene: it is expressed ubiquitously, its expression is stable 
throughout the cell cycle, and its mRNA has a long half-life.5 
The transcriptional potency of the N-terminal domain of EWS 
observed in its various tumorigenic fusion proteins suggests that 
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Ewing sarcoma family tumors (ESFT) are a group of aggressive 
solid bone and soft tissue malignancies of children and young 
adults characterized by specific chromosomal translocations 
that give rise to EWS-ETS aberrant transcription factors. 
Identification of EWS-ETS target genes and their role in tumor 
signaling networks together with the unravelling of the cell 
of origin will facilitate the translation into new treatment 
modalities for these neoplasms.
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manner, and the N-terminal EWS domain can act as a potent 
transcriptional activation domain; several fold stronger than the 
corresponding native FLI1 domain displaced by the chromo-
somal translocation. Several molecular reports have provided 
experimental evidence to confirm this view. Recent studies have 
revealed that EWS-ETS chimeric proteins also require the col-
laboration of other proteins to perform their functions, such as 
AP-1 proteins for transformation,12 or RNA helicase A, which 
acts as a transcriptional cofactor.13 Additionally, although most 
of the studies regarding the molecular function of the chime-
ric proteins in ES have focused on the altered role of the ETS 
portion, there is data suggesting that EWS modifies its activity 
when fused to ETS proteins, so that EWS-FLI1 may function 
both in transcriptional and post-transcriptional processes. In 
fact, it seems to behave as an aberrant RNA splicing factor in in 
vitro assays, blocking U1C-, TASR- and YB1-mediated splicing. 
Consequently, EWS-FLI1 may contribute to malignant transfor-
mation through disruption of RNA splicing, uncoupling gene 
transcription from RNA splicing in the pathogenesis of ES.
Targets of the Chimeric Proteins
Experimental evidence suggests two mechanisms that promote 
EWS-ETS fusion-mediated oncogenesis: (i) by acting as aberrant 
ETS transcription factors for a collection of genes, which can 
vary in their levels of expression and in their identity with respect 
to those originally regulated by the parental ETS proteins; and 
(ii) by modulating gene expression at the RNA processing stages 
of transcription control, acting as aberrant TET factors as well. 
Consequently, a major strategy towards understanding the mech-
anism by which EWS-FLI1 contributes to cell transformation has 
been to identify its putative target genes and proteins.
Up to now, only a few genes have been demonstrated to be 
direct target genes of EWS-FLI1 (Table 2): hsRPB7,14 UPP1,15 
tenascin-C,16 Id2,17 p21WAF1/CIP1,18 PTPL1,19 phospholipase D2,20 
TGFBR2,21 IGFBP3,22 MK-STYX,23 TERT,24 GLI1,25 and Aurora 
A and B.26 The rest of the genes described as interacting with EWS-
FLI1 have not yet demonstrated to be direct targets, although 
EWS may function as a transcription factor. The  RNA-binding 
motif containing the C-terminal half of EWS is replaced, in the 
EWS-FLI1 fusion protein, by the DNA-binding domain of the 
FLI1 protein. Although EWS-ETS fusion proteins function as 
sequence-specific transcription factors, the role of native EWS 
protein and the regulatory mechanism controlling the coactiva-
tor function of EWS are largely unknown.
FLI1, on the other hand, is a member of the ETS family of 
transcription factors which activate specific target genes by bind-
ing to their cognate DNA sequences through their DNA-binding 
regions, usually located at their carboxy termini.7,8 The ETS 
family of transcription factors is defined by a conserved ETS 
domain that recognizes a core DNA motif. This family of approx-
imately 30 genes, including FLI1, ERG, ETV1, E1AF, FEV and 
ZSG; controls a variety of cellular functions in cooperation with 
other transcription factors and cofactors. Target genes include 
oncogenes, tumor suppressor genes and genes related to apopto-
sis, differentiation, angiogenesis and invasion.9,10
The (11;22) translocation in ESFT leads to a fusion gene that 
encodes an oncoprotein consisting of the N-terminal domain of 
EWS and the C-terminal DNA-binding domain of transcrip-
tion factors such as ETS family, activating transcription factor-1, 
Wilms’ tumor 1 and nuclear orphan receptors.11 The replace-
ment of the native transcription activation domain(s) of FLI1 by 
the N-terminal region of EWS converts the non-transforming 
activator, FLI1, into a transforming protein with new transcrip-
tional activation potential. Sequence analysis of the translocated 
products define at least eight different types of fusion transcripts, 
depending on the specific breakpoints in the FLI1 and EWS exons 
included within the chimeric genes. Of them, the most common 
fusion (63%) is EWS exon 7-FLI1 exon 6, which is referred to as 
the type 1 fusion.
This singularity of EWS-FLI1 as the main protein actor in 
ES genesis raises the question of what are the specific functions 
of these chimeric proteins. Currently, it is widely assumed that 
EWS-ETS fusion proteins function as either aberrant transcrip-
tion factors or potent repressors. In support of this hypoth-
esis, they localize to the nucleus, bind DNA in a site-specific 
Table 1. Different fusion genes found in ESFT (and ESFT-like)
Chromosomal translocation Fusion protein Tumor type Prevalence factor (%) Reference
t(11;22)(q24;q12) EWS-FLI1 Ewing family of tumors 90 57
t(21;22)(q22;q12) EWS-ERG 5 58
t(19;der[ins.inv(21;22)]) EWS-ERG 59
t(16;21)(p11;q22) FUS-ERG 60
t(7;22)(p22;q12) EWS-ETV1 <1 61
t(17;22)(q12;q12) EWS-ETV4 <1 62
t(2;22)(q33;q12) EWS-FEV <1 63
t(6;22)(p21;q12) EWS-POU5F1 64
t(1;22)(q36.1;q12) EWS-PATZ1 Ewing family-like tumors 65
t(2;22)(q31;q12) EWS-SP3 66
t(20;22)(q13;q12) EWS-NFATc2 67
t(15;19)(q14;p13.1) BRD4-NUT 68
t(4;19)(q35;q13) CIC-DUX4 69
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to the overall effects elicited by IGF1 in ES.51 They appeared to 
be constitutively activated in ES, likely due to the presence of the 
IGF1R-mediated autocrine loop. This is consistent with results 
from gene expression studies of pediatric sarcomas, in which sev-
eral tyrosine kinases or receptor tyrosine kinases genes have been 
found to be highly associated with half of the tumor groups: KIT, 
PDGFRB, JAK1, FLT1, EGFR, PDGFRA and several FGFRs.52
Recent evidence has shown that Wnt/Frizzled signaling is 
functional in ES cell lines.53-55 Canonical Wnt/β-catenin signal-
ing enhances ESFT motility, contributing to metastasis, probably 
through either autocrine or paracrine modes of Wnt glycopro-
teins, since they are expressed in bone, muscle and soft tissues. 
Wnt proteins activate a canonical pathway that is characterized 
by accumulation of β-catenin in the cytoplasm. In the absence 
of Wnt signaling, cytoplasmic β-catenin forms a complex with 
axin, APC, GSK-3b and casein kinase I-a. Mutations in the axin, 
APC and β-catenin genes have been characterized in numerous 
human malignancies including colon cancer, malignant mela-
noma, hepatocellular carcinoma, endometrial carcinoma, ovar-
ian carcinoma and prostate cancer.56 A common outcome of these 
mutations is the accumulation of free β-catenin, mimicking con-
stitutive Wnt activation. Both canonical and non-canonical Wnt 
pathways have been shown to modulate cell motility and tumor 
metastasis, but non-canonical Wnt pathways are pending dem-
onstration in ESFT.
Secondary Alterations in ESFT
Although EWS-ETS chimeric proteins are considered the ini-
tiating molecular events in ESFT, other alterations (that will 
be considered here as “secondary alterations”) have been also 
detected. Their significance and contribution to the pathogen-
esis of ES are not completely understood yet. Henceforth we 
will discuss the main discoveries in the field. p53 mutations, 
which are frequent in ESFT cell lines,70 confer worse outcome 
but are rare in ESFT (10–20%). The same can be said for 
MDM2 and RAS mutations and other genes commonly altered 
in cancer.71-75 An exception can be made with CDKN2A locus, 
an alteration in which (a deletion in the vast majority of cases) 
has been reported as the most frequent secondary molecular 
aberration in ESFT with a 15–30% overall frequency.72,76-79 It 
they are involved in signaling pathways and gene regulation net-
works initiated by EWS-FLI1. The EWS-FLI1 target genes listed 
below are either indirect targets or need verification that they are 
direct targets (Table 2): EAT-2,27 MFNG,28 mE2-C,29 PIM3,30 
IGF1/IGF1R,31 c-Myc and p57KIP2,32 MAPT, PP1R1A, NEK2 and 
cyclin D1,33 Skp2,34 caveolin-1,35 CD99,36 zyxin,37 DAX1/NR0B1,38 
NKX2.2,39 cholecystokinin,40 VEGF-A,41 NOTCH-p53,42 thrombo-
spondins 1 and 2,43 EZH244 and TOPK.45 Based on a stable EWS-
FLI1 shRNAi model constructed in TC71 (ES type 1 cell line), 
Herrero-Martín et al.45 revealed a set of potential new targets for 
the ES fusion protein, including LSM1, BEX2, TK1 and EIF4E.
Much of the understanding about the nature of the targets of 
EWS-ETS is derived from studies of oncogenic fusions that arise 
from gene rearrangements after chromosomal translocation. Even 
more research has been devoted to understanding the mecha-
nisms of action of the ES chimeric proteins themselves. However, 
although extensive work has been performed using cellular, 
molecular and genomic lines of attack, little knowledge has been 
reported using a proteomic approach. To assess the contribution 
of the N-terminal domain of the EWS protein to the formation 
of human solid tumors, it is important to understand the normal 
function(s) of EWS, but this point is not well characterized yet. 
Nonetheless, a handful of proteins have been suggested as inter-
acting with EWS-FLI1, either directly or indirectly: hsRPB7,14 
TERT,46 heat shock proteins,47 HSP90,48 IGF1,49 or Interferon 
(IFN)α/β receptor.50
Taken all these observations together, we can conclude that 
the fusion protein EWS-FLI1 exerts a certain degree of control 
in different routes of tumor development, maintenance and pro-
gression in ES: cell proliferation and survival (by activation of 
targets IGF1, MYC and NKX2.2, among others); escape from 
growth inhibition, senescence and apoptosis (by inhibition of 
p21, p57kip, TGFBR2 and IGFBP3); and upregulation of criti-
cal genes involved in neural tube and neural crest development 
(NKX2.2, cholecystokinin).
Cellular Signaling Pathways in ES
An inquisitive look at the cell signaling pathways altered in ES, 
and more specifically at the changes in particular molecules 
involved in them, such as cell surface adhesion molecules, receptor 
tyrosine kinases, growth factors and transcription factors would 
constitute a valuable strategy for identifying potential candidates 
for therapeutic intervention and diagnostic development (Fig. 1). 
The most relevant signaling routes reported to be altered in ES 
are tyrosine kinase pathways and the Wnt signaling pathway.
ESFT proliferation and maintenance is determined by auto-
crine and paracrine activation of growth factor receptors and 
their corresponding ligands, such as insulin-like growth factor 
1 (IGF1) and its receptor insulin-like growth factor 1 recep-
tor (IGF1R).31 EWS-FLI1 shRNA interference in ES cell lines 
affected the IGF1/IGF1R survival pathway and its downstream 
targets.45 An analysis of the contribution of the two major path-
ways of the intracellular IGF1R signaling cascade suggested that 
both the mitogen-activated protein kinase (MAPK) and phos-
phatidylinositol-3-kinase (PI3K) signaling pathways contributed 
Table 2. A summary of EWS/FLI1 genetic targets identified to date 
(references found in the text)
Regulation Gene name
(A) Direct targets
Upregulated
RPB7/POLR2G, TNC, UPP1, ID2, TERT, PTPL1/PTPN13, 
PLD2, MK-STYX, GLI1, Aurora A and B
Downregulated p21/CDKN1A, TGFBR2, IGFBP3
(B) Indirect targets
Upregulated
EAT-2/SH21B, MFNG, UBE2C, CCND1, MAPT, PP1R1A, 
NEK2, MYC, PIM3, NKX2-2, CCK, CAV1, CD99, 
VEGF-A, EZH2, TOPK/PBK, IGF1/IGF1R, DAX1/NR0B1
Downregulated
p27/CDKN1B, p57/CDKN1C, ZYX, NOTCH-p53, 
 thrombospondin 1 and 2
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On the other hand, the absence of p53 mutations in most ESFT 
tumors was not consistent with in vitro results: this protein and/or 
its pathway was expected to be altered because in vitro experiments 
showed how cell types with different origins cannot be transformed 
by EWS-ETS because of p53 activation and subsequent cell cul-
ture growth arrest and induction of senescence.80 Moreover, forced 
expression of p53 in vitro demonstrated that p53 is not mutated in 
tumors and its pathway is functional in ESFT cell lines.81
Another gene involved in the G
1
 to S cell cycle checkpoint, 
p27Kip1, has been shown to be absent in ESFT. Low expression lev-
els were detected in most ES patients (76%) with a remarkably 
worse survival. EWS-FLI1 promotes the cell cycle progression 
through suppression of the expression of this cyclin-dependent 
has been proven that the loss of the CDKN2A locus has a 
marked clinical outcome as the event-free survival (EFS) is 
worse in ES patients with p16INK4 and p14ARF mutation/deletion 
than in those without the mutation/deletion.72,77,78 But also it 
has been related with the stage of the ES patient and a poor 
chemoresponse.77,79 Thus, the loss of CDKN2A locus has a clin-
ical usefulness in identifying a subset of ES patients with poor 
prognosis. It is tempting to propose that the loss of products 
from this locus, p16INK4 and p14ARF, could cooperate with one 
of the best characterized EWS-ETS downstream targets, cyclin 
D1,33 to release cell cycle initiation from its negative regulators, 
rendering it independent from extracellular signals and other 
controls.
Figure 1. Regulation and role of EWS/FLI1 direct targets in the most important signaling pathways described in ESFT. Signaling pathways involved 
in ES proliferation-survival and phenotype are delimited in dashed areas. Canonical pathway interactions are depicted by continuous lines, whereas 
dashed lines represent possible pathway interactions. Red and green colors mean up-regulation and down-regulation, respectively. EWS/FLI1 direct 
targets are represented in boxes: kinases are shown as hexagons, phosphatases as ovals, transcription factors as octagons and the remaining targets 
are shown as rectangles.
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EWS-ETS fusions into diverse cellular systems gave rise to differ-
ent responses like induction of apoptosis, growth arrest or dedif-
ferentiation.80,96-98 Considering that most ESFT occurs in bone 
and soft tissue, bone marrow-human mesenchymal stem cells 
(MSCs) may serve as one cellular source susceptible to EWS-
FLI1 transformation. Bone marrow-human MSCs, which are 
classic mesodermal derivatives, express an extensive assortment 
of neural genes, and therefore, are predisposed to differentiate 
to neural and glial lineages.99 The EWS-FLI1 fusion has been 
shown to impose a neural crest parasympathetic lineage direc-
tion to the cells but inhibits terminal differentiation and could 
act through the Wnt signalling pathway, a possible common 
mechanism for vertebrate neural crest induction.100,101 EWS-FLI1 
upregulates critical genes in neural crest development, acting as 
a cell lineage determinant rather than a pure “oncogene” and 
EWS-ETS expression is considered to be the initiating malignant 
event of ESFT tumorigenesis.101-103
In fact, the development of ES-like tumors from MSCs has 
been already described in mice.103,104 Gene expression profile 
analysis of tumor-derived cells revealed upregulation of known 
EWS-FLI1 gene targets, including MYC and ID-2, and repres-
sion of p21 and TGFβRII, both of which have been shown to be 
downregulated in ES cells. Furthermore, these tumors were highly 
sensitive to IGF1R inhibition, a hallmark of ES, and expressed 
ES-associated markers, including NSE and CD99. Importantly, 
bone marrow MSCs used in this study expressed a functional p53 
in addition to retaining the p16INK4A/p19ARF locus.104
In immortalized human MSCs, the phenotype and ontogen-
esis of human MSC-TERT20 tumors were consistent with the 
hypothesis that sarcomas may arise from MSCs.105 Riggi et al.44 
have shown that expression of EWS-FLI1 in human MSCs is 
able to induce a gene expression profile highly similar to that of 
ESFT although the cooperation of additional genetic alterations 
is required for a full tumoral transformation. Recent evidence 
suggests that five events are required to transform human MSCs. 
In this study, retroviruses encoding for the catalytic subunit of 
human telomerase (hTERT), HPV-16 E6 and E7, SV40 small 
T antigen (ST), and an oncogenic allele of H-Ras (H-RasV12) 
were used to induce transformation.106 Functional IGF1R 
expression has been shown to be a pre-requisite for EWS-FLI1-
mediated transformation, underscoring the importance of the 
IGF1/IGF1R pathway in the initial phase of ESFT develop-
ment.45,107 Furthermore, the DNA binding ability of EWS-
FLI1 is required for IGF1 induction in bone marrow-human 
MSCs.44 IGF1/IGF1R signaling has been observed to be critical 
during the initiating phases of ES development, and its block-
ade induces growth arrest and apoptosis in ESFT cell lines.108 
The polycomb group gene EZH2 is another EWS-FLI1 can-
didate target gene that was induced in human MSCEWS-FLI-1. 
EZH2, implicated in the maintenance of glioblastoma stem 
cells,109 may help to achieve the tumorigenic phenotype of ES 
by preventing cell senescence while promoting survival and 
proliferation and hindering differentiation.110 This is supported 
by a study of EZH2 repression, which resulted in the reduction 
of ESFT cell proliferation and tumorigenicity.44 In a complemen-
tary approach, the profiles of different EWS-FLI1-silenced ES 
kinase inhibitor via activation of the proteasome-mediated degra-
dation pathway. Forced p27Kip1 expression in ES cell lines proved 
its ability to reduce cell growth and promote apoptosis in vitro and 
in vivo.32,34,82
The tumor suppressor, p21WAF1 shows a similar situation, with a 
55% of ES cases showing loss of expression.32,83 The activity of the 
p21WAF1 is negatively regulated by EWS-FLI1 fusion protein through 
at least two ETS-binding sites in its promoter.84 Silencing of EWS-
FLI1 in a wild-type p53 context resulted in increased p21WAF1.42 As 
the fusion protein interacts with the p300 cotransactivator and 
suppresses its histone acetyltransferase activity, the use of a histone 
deacetylase inhibitor results in the induction of p21WAF1.84,85 Thus 
p21WAF1 could be a target for a molecularly based therapy for ESFT. 
As can be easily concluded, abrogation of G
1
-S transition repressors 
accounts for all the secondary alterations identified in ESFT sug-
gesting that molecular events targeting these regulators are needed 
for tumor development.
Another set of studies has enhanced our understanding of 
the genomic imbalances in ESFT, making use of diverse tech-
niques such as comparative genomic hybridization on metaphase 
spreads (CGH), CGH array, fluorescent in situ hybridization 
(FISH) or multiplex ligation-dependent probe amplification 
(MLPA).70,77,78,86-95 Results from these works gave similar esti-
mations of the abundance of genomic aberrations, showing an 
overall incidence of 80% of cases bearing copy number altera-
tions (CNA). Specifically, gains of chromosomes 1q, 8 and 12 and 
losses of 9p and 16q are the main alterations reported by CNA.
The prognostic impact of these aberrations is still unclear 
although studies support an adverse survival for the most frequent 
alterations (1q, 12 and 16q), especially in those studies with larger 
sample sizes. Remarkably, the gain of chromosome 8, present in 
50–60% of ES, has never demonstrated prognostic value in clinical 
correlations. However, it seems clear that the global amount of CNA 
correlates with poor survival. Data has been divided by two types 
of thresholds for this sort of analysis: overall chromosome number 
above 50, based on karyotyping, and CNA above three, by CGH 
studies. Patients above these thresholds clearly demonstrated worse 
survival. Besides large chromosomal aberrations, CGH array stud-
ies using oligonucleotide platforms have unveiled the existence of 
very short CNA (less than 100 kbs) not detectable with other tech-
nologies.93 The loss of the CDKN2A locus was the only one found 
to be recurrent; reinforcing its role as a major secondary alteration.
Finally, a few studies have contrasted the impact of copy number 
changes on the transcriptome.91,93 The first of these studies deter-
mined that those samples showing genomic instability (more than 
three CNA) displayed overexpression of genes implicated in cell 
cycle regulation, chromosomal segregation and mitosis.91 Other 
authors have selected a list of candidate genes based on gene copy-
expression level correlation studies, and tried to validate one of 
them, HDGF, as a prognostic marker, although they did not find it 
statistically relevant.93
ESFT Cell Type of Origin
The cellular context plays a fundamental role in ES pheno-
type, as proven by the fact that the experimental insertion of 
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The Pediatric Preclinical Testing Program supported by the 
National Cancer Institute aims to identify new drugs active 
against childhood cancers. The program makes use of a panel 
of 61 childhood tumor xenografts (four of them are ES xeno-
grafts) in which tumor-type selectivity of novel treatments is 
tested. The ES xenografts were obtained by using CB17SC-M 
SCID-/- mice implanted with ES cell lines (SK-NEP-1; EW5, 
EW8, TC-71).121
Xenograft models have been used to gain knowledge about 
the pathogenesis and histogenesis of ES. Tumors with charac-
teristics of ES were developed in mice implanted with murine 
primary bone-derived cells and mesenchymal progenitor cells 
expressing EWS-FLI1.103,104 Recently, we identified TOPK, a 
kinase involved in cell proliferation and motility, as a target of 
EWS-FLI1 by using an RNA interference system to knockdown 
EWS-FLI1 in an ES cell line. NOD/SCID mice implanted with 
the interfered cells developed smaller tumors than controls.45
Moreover, several specific ES metastatic models have been also 
published. In these models, ES cells were injected through the 
mouse tail vein. These models resemble the pattern of metastatic 
diffusion of ES in humans, including skeletal and extraskeletal 
locations.122,123 Gonzalez et al.118 reported a different strategy to 
induce metastasis formation in mice. They injected cells trans-
duced with the EWS-FLI1 fusion types 1, 2 and 3 into the left 
cardiac ventricle of athymic mice. The aim of this approach was to 
overcome the limitation imposed by the fact that lung metastasis 
formation, after injection of cells via tail vein, may not necessarily 
reflect metastatic activity, as lungs bear the first capillary bed that 
injected cells face after tail vein injection. This model could be 
useful to test the effects of new inhibitors of tumor growth.
However, despite the great amount of information that these 
xenograft models provide, they also face many drawbacks. For 
instance, the normal architecture present in the patient tumor 
specimens is altered in xenografts and the genetic heteroge-
neity is diminished. The tumor heterogeneity characteristic 
of the original ES is lost as a result of the selective pressure 
of cell culture or tissue explantation. Moreover, they do not 
accurately reflect the course of human disease. Therefore, the 
data obtained by using these models should be examined care-
fully, especially when a new compound is tested. For all these 
reasons, we believe that xenograft models should be considered 
as an intermediate step between cell culture and murine cancer 
models, and therefore they should be named more properly as 
“animal cultures.”124
Genetically engineered models in ESFT. So far, no murine 
genetically engineered model (GEM) of ES has been created and 
importantly, there has been no report indicating any attempt to 
achieve it until recently.125,126 The embryonal lethality, due to 
the expression of the EWS-ETS fusions, is probably the main 
explanation for the lack of a GEM of ES to date.126,127 To avoid 
embryonic lethality, a key approach could be to drive the expres-
sion of EWS-FLI1 exclusively in MSCs, as they seem to be the 
cells of origin for ES.128 In this regard, it would be important to 
identify more specific mesenchymal genes by which the expres-
sion of EWS-FLI1 could be directed, thus avoiding the expres-
sion in hematological tissues, as it induces leukemia.126 Another 
cell lines converge on that of mesenchymal stem cells,111 and the 
“core” EWS/FLI1 transcriptional signature has been correlated 
with that of human MSC.112,113
Bone marrow-human MSCs may be the right cells in the right 
place for EWS-FLI1-mediated pathogenesis, and their capability 
to migrate from the bone marrow niche would help to explain the 
extraosseous locations of ESFT.102,103,114 It is important to study 
these progenitors or even earlier precursor cells, whose devel-
opmental program seems to be deranged and blocked early in 
differentiation, in the search for specific molecular markers that 
would help to describe the ontogeny of the disease, and would 
allow the early detection of cells involved in sarcomagenesis. 
Because of the lack of knowledge about the first molecular events 
involved in translocation, the characterization of bone marrow-
human MSCs from ESFT patients and healthy donors and the 
comparison at several levels (transcriptomic, epigenetic and 
proteomic ones), would be a key factor in highlighting the earli-
est tumorigenic processes. Recently, a subpopulation of cancer 
stem cells in ES have been identified and characterized. These 
CD133+ tumor cells are able to initiate and maintain tumoral 
growth through the course of transplantations in immunodefi-
cient mice and show a high degree of plasticity as MSCs.115
Taken together, all these data support the notion that MSCs 
would be suitable candidates as ES precursor cells as has been 
proposed already for other sarcomas. Furthermore, these data 
point towards MSCs as putative targets for more effective thera-
peutic strategies.116,117
Animal Models in ESFT
From cell culture to mouse models. The information obtained 
from tissue culture studies using human and animal cell lines 
has provided great and inestimable information to the scientific 
community working on sarcomas and particularly on ESFT. The 
research done with cell lines has made it possible to infer the gene 
fusion role in the pathobiology of ES and also to discover new 
genes involved in this neoplasia.32,118 Cell culture models also pro-
vide the primary platform for the testing of new drugs.49 However, 
in vitro conditions exert selective pressure on ES tumor cells and 
research has shown that only those tumor cells harboring particu-
lar molecular alterations are prone to growth in cell culture.119
Moreover, cancer and particularly ES is a complex disease in 
which microenvironment and surrounding cells (normal, stromal 
and immune cells) play a crucial role. In fact, some aspects of 
ES development, for instance angiogenesis or metastases, can not 
be assessed by cell culture studies alone. Therefore, the informa-
tion obtained by in vitro studies needs to be confirmed and there-
fore should be taken into account carefully. For these and other 
reasons, the development of animal models in ES is an issue of 
paramount relevance. As reviewed by Beltinger and Debatin,120 
few animal models of ES have been developed by implantation 
of tissue of murine origin into immunocompetent mice (synge-
neic model). At present, several models created by implantation 
of tissue of human origin (xenogeneic or xenograft model) have 
been reported.48,103 These models have been used mainly to test 
the effects of novel therapeutic compounds.
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tissues. Interestingly, induction of FUS-CHOP is not lethal 
for the mouse, as seen with other sarcoma fusion genes such as 
EWS-FLI1 and EWS-ERG.126,127,130
In some transgenic mice, the expression of gene fusions is 
controlled with exogenous substances such as tetracycline or its 
analog, doxycycline. This approach has identified the role played 
by BCR-ABL1 in both the induction and maintenance of acute 
B-cell leukemia.131 More recently, Lin et al.125 created a condi-
tional transgenic GEM by inducing the expression of EWS-FLI1 
in the MSCs of embryonic limb buds using a Cre-Lox system, 
which did not induce tumors. Only in a setting of p53 deletion 
did mice develop poorly differentiated sarcomas but not ES.
Another large group of models expresses the fusion genes 
from their native promoters through knock-in technology. These 
models use homologous recombination in ESCs to induce gene 
fusions and therefore transfer them into the mouse germline. The 
conditional knock-in models make use of specific recombinases, 
allowing a spatio-temporal control of the chimeric gene expres-
sion. The P1 bacteriophage Cre-lox system is the most widely 
employed. To generate Cre-lox mice expressing the fusion gene, 
it is necessary to engineer two transgenic murine lines: a Cre 
mouse and a loxP mouse. The Cre mouse harbors the Cre recom-
binase gene under the control of a tissue specific promoter. Cre 
recombinase mediates the recombination between loxP sites, a 
pair of inverted, repeated DNA elements. The loxP mouse can 
be engineered to harbor the chimeric fusion gene, plus a stop cas-
sette upstream of the fusion site flanked by loxP sites in the same 
orientation. Depending on the orientation and location of the loxP 
sites, recombination mediated by Cre induces deletion, inversion 
or translocation of the sequence of interest. After breeding the 
two mouse lines, expression of Cre induces the excision of the stop 
cassette and consequently the expression of the fusion gene.
Higuchi et al.132 generated a transgenic mouse harboring 
a conditional knock-in allele containing a loxP-STOP cassette 
placed upstream of the AML1-ETO fusion site. The fusion 
gene was induced after crossing the AML1-ETO murine line 
important aspect that could help to explain the absence of a 
GEM ES model is the different genetic background of mice as 
compared to humans. As has been pointed out earlier, Hancock 
and Lessnick,112 compared the gene expression profiles of dif-
ferent ES models with human ES samples. They found strong 
correlations between human-based EWS-FLI1 models and ES. 
However, none of the murine-based model systems showed any 
correlation to ES samples. The data demonstrated that models 
using murine cellular backgrounds perform poorly in general, as 
compared to human-based ones. One possibility is that EWS-
FLI1-mediated pathways in mouse cells could be different than 
those in the original human disease. Another possibility is that 
crucial EWS-FLI1 binding sites may not be present in the mouse 
genome. Alternatively, coregulators of the EWS-ETS chime-
ric proteins (such as coactivators or cooperating transcription 
factors) might interact differently in the mouse.112
Overcoming the problem of the embryonic lethality induced 
by gene fusions, different genetically engineered models of 
sarcomas, such as liposarcoma, alveolar rhabdomyosarcoma and 
synovial sarcoma, as well as of some malignant hematological 
disorders have been generated (reviewed in Ordóñez et al. submit-
ted). Chromosomal translocations and their corresponding gene 
fusions are common events in all of these malignancies, playing 
a crucial role in the initial steps of sarcomagenesis.129 A general 
view of the strategies used and their advantages and disadvan-
tages could be of help to understand why all attempts to generate 
an ES mouse model have failed (Table 3).
Some transgenic mice have been engineered to induce the 
expression of fusion genes in a non-physiological manner under 
the control of exogenous promoters or enhancer elements 
through the injection of cDNA constructs into fertilized oocytes 
or through gene targeting in embryonic stem cells (ESCs).124,130 
Pérez-Losada et al.130 generated a model of liposarcoma by 
pronuclear injection into fertilized eggs, of a cDNA construct 
including the human FUS-CHOP gene under the control of the 
elongation factor 1α promoter to direct expression to all mice 
Table 3. Genetically engineered models of common fusion genes found in sarcomas
Ref. Model Fusion Promoters Expression place Phenotype
130, 136 Transgenic FUS-CHOP EF1-α All tissues Liposarcoma
134 Conditional knock-in (Cre-loxP) SYT-SSX2
Rosa26 (loxP mice) 
Myf5 (Cre-mouse) 
Myf6 (Cre-mouse) 
PAX-7; PAX3  
(Cre-mouse)
Myoblast 
Myocyte, Myofiber 
Progenitors cells
Sinovial 
myophathy; 
lethality
133
Conditional knock-in (Cre-loxP) 
Knock-out Trp53 or Ink4/ARF
PAX3-FKHR Myf6 (Cre mouse) Myofiber
No tumor  
rhabdomyosarcoma
133 Conditional knock-in (Cre-loxP) PAX3-FKHR Pax7 (Cre-mouse) Progenitor cells (satellite) No tumor
126 Conditional knock-in (Cre-loxP) EWS-FLI1
Rosa26 (loxP mice) 
MX1-cre
Bone marrow liver, spleen, 
and hematopoietic tissues
Myeloid/erytroid 
 leukemia
127 Invertor EWS-ERG
EWS endogenous 
(loxP mice) 
Rag1 (Cre-mouse)
Lymphocyte Leukemia
125
Conditional transgenic (Cre-loxP) 
deletion of p53
EWS-FLI1 Prx1 (Cre-mouse)
Primitive mesenchymal 
tissues of the embryonic 
limb bud
Poorly differentiated 
sarcomas
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cassette flanked by loxP sites was knocked-in to the EWS gene 
but in the reversed orientation with respect to the direction of 
transcription. Later, Cre recombinase, under the lymphocyte-
specific Rag1 promoter, mediated inversion of the ERG gene and 
produced the EWS-ERG gene fusion, subsequently generating 
leukemia.127 The invertor model was later used for a model of 
B-cell lymphomas by expression of MLL-AF4.135
Immune System Role in ESFT: Significance of 
Immunotherapy
One of the mechanisms of tumor relapse is escape from immu-
nity. Understanding the relevant molecular connections between 
tumor development and the immune system will help to develop 
more effective therapies. ES is not able to induce an effective 
antitumor response, which has been attributed to low level 
major histocompatibility complex (MHC) expression and lack 
of co-stimulatory surface molecules. Immunotherapy is an emer-
gent and exciting treatment field in ESFT and several different 
approaches have been already tested.
Fas-FasL interactions and the death-receptor pathway play 
a central role in the regulation of the immune response. ESFT 
are resistant to the cytolytic death-receptor pathway but main-
tain their sensitivity to the perforin-granzyme pathway, which 
could be exploited for inducing apoptosis; for example through 
restoration of caspase-8 expression.137,138 Despite some ES cell 
lines expressing a non-functional FasL, it is possible to induce 
Fas-mediated apoptosis after IFNγ preincubation and/or 
cycloheximide treatment through the generation of cytotoxic 
T-cell lymphocytes (CTLs).139
Survival in ESFT is not improved by allogeneic stem cell 
transplants (SCT),140 although some patients benefit from 
high-dose chemotherapy plus autologous SCT.141,142 The cytokine 
interleukin-2 (IL-2) has been used with SCT patients to reinforce 
antitumor immunity.143,144 Side effects have been circumvented 
by the use of IL-2 transgenic ES cells showing an increase in the 
number of T and natural killer (NK) cells and a reduction of 
tumoral cell growth in vitro and in vivo.145 Thus immunomod-
ulation using cytokine-induced cells as tumor-reactive T cells 
and/or NK cells is another treatment option for advanced-stage 
ESFT.146 NK cell cytotoxicity depends on the combination of 
NKG2D and DNAM-1 signaling pathways and is increased 
by activation with interleukin-15. ESFT cells are potentially 
susceptible to NK cell lysis due to the expression of activating 
NK cell receptor ligands.147 Dendritic cell (DCs)-based immu-
notherapy may be a promising complementary strategy as these 
antigen-presenting cells are capable of stimulating T-cells.148,149 
DC-based vaccines have already been shown to be effective in 
ESFT as tumoral growth reduction is achieved in vitro and in 
vivo through stimulated CTLs.150
A wide search has been done in ESFT for tumor-associated 
antigens (TAA) in order to identify targets for therapeutic cancer 
vaccines. Due to their specific expression, EWS-ETS chimeric 
proteins are perfect candidates for TAA targeting. Peptides span-
ning the breakpoint of these fusion transcription factors with 
MHC I and II binding motifs could be susceptible to CTLs 
with a transgenic murine line expressing Cre recombinase 
under the control of the IFNα/β-inducible Mx1 promoter. This 
promoter is activated in vivo after treatment with IFNα/β 
(or  polyinosinic-polycytidylic acid, pI-pC), which induces Cre 
expression exclusively in those cells harboring IFNα/β receptors. 
After expression of Cre recombinase under the IFNα/β inducible 
Mx1 promoter, the stop cassette was eliminated in hematopoietic 
and non-hematopoietic tissues. However, the mice retained the 
fusion gene that was expressed exclusively in myeloid progenitors 
under the endogenous AML1 regulatory sequences.
In a recent report, Torchia et al.126 circumvented the embry-
onic lethality induced by the chimeric protein, generated a 
transgenic mouse of EWS-FLI1 by using a knock-in condi-
tional approach, using a loxP-flanked (floxed) transcription stop 
cassette (loxP-STOP-loxP). As described by Higuchi et al.132 a 
Cre-inducible recombinase under the control of the Mx1 
promoter was used. However, in contrast to the aforementioned 
study, EWS-FLI1 was not under the control of the fusion 
promoter but rather, was under the control of the murine ubiqui-
tous promoter Rosa 26. This is the first GEM mouse of EWS-FLI1 
published to date. However, EWS-FLI1 expression following 
Cre induction after a single administration of pI-pC did not 
produce ES tumors, but rather myeloid/erythroid leukemia, 
which caused animal death about 2 w after administration. Even 
a group of animals that were not administered pI-pC developed 
a similar pathology as compared with pI-pC treated animals, 
indicative of a basal expression of Cre, and consequently of 
EWS-FLI1 protein.
Keller et al.133 have used the conditional knock-in strategy 
to generate an alveolar rhabdomyosarcoma model, by induc-
ing the expression of the PAX3-FKHR fusion in skeletal 
muscle cells of a Myf6-Cre murine line. However, the expres-
sion of PAX3-FKHR did not produce an alveolar rhabdomyo-
sarcoma phenotype by itself, so it was necessary to inactivate the 
Ink4a/Arf and Trp53 genes. Recently, a conditional knock-in 
model of synovial sarcoma has been described in which the 
SYT-SSX2 fusion was expressed in Myf5 expressing myoblasts. 
When the expression of the chimeric gene occurred in cells of 
skeletal muscle lineage other than myoblasts, animals suffered 
myopathy or embryonic lethality but not synovial sarcoma.134 
This fact clearly indicates the crucial relevance of an accurate 
selection of the cellular context for fusion gene expression in 
order to avoid lethality and other side effects. However, some-
times it is not possible to avoid minimal but meaningful tran-
scription levels of fusion genes, which provoke lethality. Such 
minimal transcription occurs with EWS-FLI1 in ES and MLL-
Af4 in hematological malignancies.126,127
A different strategy used to generate GEM mouse is the 
“invertor model,” a new version of knock-in strategy using loxP 
sites. In this model a floxed cassette is introduced into the intron 
of a target gene by homologous recombination in ESCs but the 
target gene is oriented in the reverse direction for transcription. 
Only after Cre recombinase expression is the cassette correctly 
orientated so that the fusion gene can be generated. This strat-
egy was used for generation of T-cell lymphomas by conditional 
expression of EWS-ERG in hematopoietic cells. An ERG invertor 
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GGAA-containing elements are enriched close to EWS-FLI1-
upregulated genes but not downregulated ones.184,185 Even micro-
satellite polymorphisms may confer differences in susceptibility 
to ES.185 It has been shown that the ability of the EWS-FLI1 
to bind DNA and the strength of the transcriptional activa-
tion depend on the number of consecutive GGAA motifs.184,186 
Recently glutathione S-transferase M4 (GSTM4) has been identi-
fied as a direct EWS-FLI1 target gene in ES. EWS-FLI1 binds 
the GSTM4 promoter and regulates its expression through a 
GGAA-microsatellite motif. GSTM4 inhibition reduces onco-
genic transformation and increased sensitivity of ES cells to che-
motherapeutic agents and high levels of GSTM4 expression has 
been associated to a worse outcome in ES patients. This study 
defines a wider role for GGAA-microsatellites in EWS/FLI tran-
scriptional regulation than previously appreciated.187
The latest therapeutic approaches in ESFT are quite diverse 
and pointed toward several different pathways as manipula-
tion of oxidative stress through targeting specific cellular anti-
oxidants,188 disruption of EWS-FLI1 interactions—for example, 
with RNA helicase A in order to promote apoptosis,189 use of 
antagonists of the receptors of the neuroendocrine peptide chole-
cystokinin,190 proteasome blockers as bortezomib utilized either 
alone or in combination with other drugs to overcome chemo-
resistance,191,192 and new classes of kinase inhibitors.193-196 The 
availability of a well-defined preclinical model, the pediatric 
preclinical testing program, is helping to develop novel treatment 
modalities.121,196,197
Blocking of angiogenesis and vasculogenesis seems to be one 
of the most promising therapeutic alternatives in ESFT treat-
ment. Both processes are critical in the growth and expansion 
of ES. Bone marrow cells participate in the generation of new 
vessels that supports the growth of ES and vascular endothe-
lial growth factor 165 (VEGF165) plays a crucial role in this 
process. Blocking VEGF receptor 2 with the antibody, DC101, 
suppresses tumor growth, reduces tumor vessel density, inhibits 
the migration of vessel endothelial cells and increases apopto-
sis.198 VEGF165 is also involved in the ES-induced bone lysis as 
it modulates the expression of a critical osteoclastogenic factor, 
the receptor activator NFkB, thus contributing to the meta-
static process.199 Silencing of VEGF165 achieves a reduction 
in metastases,199 as also happens in an ES orthotopic xenograft 
model after  platelet-derived growth factor receptor beta inhi-
bition.200 Delta-like ligand 4 and the MEK kinase, MEKK3, 
have been recently described as important actors in ES vascu-
logenesis.201,202 Delta-like ligand 4 is necessary for the forma-
tion of bone marrow-derived pericytes/vascular smooth muscle 
cells,201 and MEKK3 is required for tumor vessel generation.202 
Molecular-targeted therapies against these pro-angiogenic and 
pro-vascular factors will hopefully impair ESFT development 
and spreading as preclinical evaluation studies confirm.203,204
Therefore the new treatment strategies with respect to ESFT 
are not only focused on targeting the chimeric fusions EWS-ETS 
or their target genes. The influence of tumor microenvironment 
through key pathways for ES proliferation and dissemination 
including angiogenesis or vasculogenesis or the increasing impor-
tance of the role of microsatellites point towards novel therapeutic 
or DCs killing.151-153 Several other TAA have been proposed: 
cancer-germline genes (CGGs),154 papillomavirus binding factor 
(PBF),155 human leukocyte antigen (HLA),156 membrane-associ-
ated phospholipase A1beta (LIPI),157 or cofactors such as 4-1BBL 
that could help to stimulate the immune response.158
Recently, a clinical study has been conducted in which patients 
with metastatic or recurrent ESFT receive autologous T cells and 
DCs pulsed with peptides derived from sarcoma-specific trans-
location breakpoints and E7, a peptide known to bind HLA-A2, 
plus IL-2. Patients experienced minimal toxicity and favorable 
survival.159 Thus, several trials are being conducted with the 
purpose of integrating immunotherapy into multimodal treat-
ment regimens in ESFT, thereby leading to more effective and 
specific therapies.
Novel Treatment Modalities for ESFT
Knowledge of the mechanisms of malignancy of the EWS-ETS 
fusion proteins and their target genes have allowed the devel-
opment of directed molecular targeted therapies in ESFT. An 
IGF1/IGF1R signaling pathway blockade based on the use of 
neutralizing antibodies and/or small-molecule compounds repre-
sents the best example of an ES molecular-based treatment.160-163
The relevance of some EWS-FLI1 target genes, such as 
DAX1/NR0B1,164,165 GLI1,166 NKX-2.2,167 or caveolin-1,168 in the 
ESFT pathogenesis has been confirmed by several studies thereby 
making them attractive treatment objectives. Some other novel 
actors, with putative tumorigenic roles and thus susceptible to 
therapeutic intervention, have been identified in ES. For example, 
polo-like kinase 1, which is highly expressed in other sarcomas,169 
or Src family tyrosine kinases such as Lyn, which when inhibited, 
diminishes tumor growth and reduces lung metastases of ES.170 
BMI-1 is a polycomb group gene that promotes anchorage-in-
dependent growth in vitro and tumorigenicity in vivo, indepen-
dent of CDKN2A repression, through modulation of adhesion 
pathways.171 Caspase 3 has been revealed as another direct target 
gene of EWS-FLI1.172 Furthermore, proangiogenic factors such as 
stromal cell-derived factor-1, which stimulates vasculogenesis,173 
may also turn out to be suitable targets.
During the past few years not only have some well-known 
EWS-ETS targets been confirmed and novel ones been identified 
but additionally, some new useful molecular markers of progno-
sis,174-178 recurrence,179 metastasis or drug resistance have been 
discovered.176,180
Post-translational modifications of the chimeric fusions such 
as O-GlcNAcylation or phosphorylation in response to DNA 
damage could affect their transcriptional activity although how 
these modifications work in ES is an unresolved question.181,182 
Methylation could be also an important phenomenon.183
As has been shown recently, microsatellites sequences 
seem to play an important role in ESFT tumorigenesis.184-187 
Microsatellites have been often regarded as useless or “junk” 
DNA regions but their role in ESFT malignancy has been 
proven. EWS-FLI1 modulates the expression of some direct 
target genes such as NR0B1 through binding to GGAA mic-
rosatellites present in their promoters. These highly repetitive 
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of the secondary genetic alterations and the discovery of more 
accurate markers of prognosis and relapse are the main tasks to 
accomplish.
Resolving these questions will shed light on ES pathogenesis 
and hopefully will help to identify novel therapeutic modalities.
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